Luminex Corporation has announced that xMAP® Technology is playing a key role in the biobank profiling research within the Human Protein Atlas (HPA) project.
In the latest release of the protein atlas, the HPA announced coverage of over 80% of the human protein-coding genes and RNA expression data for more than 90% of the genes.
The goal of the Human Protein Atlas project is to explore the entirety of the human proteome using antibody-based proteomics. This pioneering project leverages Luminex's xMAP Technology for biobank research of body fluids.
The high-throughput biomarker screening approach combines Luminex technology with several thousand antibodies through multiplexed screening of over 380 targets per well per run.
"We are very excited to be part of this revolutionary systematic exploration of the next frontier in human biology, the human proteome," said Patrick Balthrop president and CEO of Luminex.
Balthrop continued, "This project goes beyond the genome to advance the understanding of human disease and cell function. We look forward to continuing to partner on these groundbreaking projects that advance research by developing products that help scientists make discoveries, and advance science to ultimately improve the health and quality of life for all."
"In addition to our own research, we collaborate with partners to identify interesting candidate biomarkers for a wide range of diseases," said Jochen Schwenk, Ph.D., Associate Professor of Translational Proteomics at KTH Royal Institute of Technology and facility manager at the Science for Life Laboratory.
Schwenk continued, "The Luminex xMAP Technology has made it possible for us to perform truly flexible and very high-throughput screening of biomarkers using the HPA antibodies on large numbers of samples. We then develop downstream biomarker validation assays on the same xMAP Technology."